Exercising in the COVID-19 era: implications in non-alcoholic fatty liver disease (NAFLD).
Philip O'GormanSuzanne NorrisPublished in: BMJ open gastroenterology (2021)
COVID-19 is a major public health pandemic. Risk factors for severe infection and poorer outcomes include cardiovascular disease, obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). Lifestyle interventions, including diet and physical activity modifications, are the current recommended treatment for NAFLD. In this communication, the authors discuss the crossover link between NAFLD and severe COVID-19 infection and the impact of essential public health measures to suppress the spread of COVID-19 on exercise and physical activity participation in patients with NAFLD. The future of exercise prescription and the potential use of digital technology in addressing NAFLD healthcare needs in the COVID-19 era are also explored.
Keyphrases
- physical activity
- coronavirus disease
- sars cov
- public health
- cardiovascular disease
- healthcare
- body mass index
- weight loss
- metabolic syndrome
- respiratory syndrome coronavirus
- type diabetes
- early onset
- sleep quality
- coronary artery disease
- randomized controlled trial
- insulin resistance
- weight gain
- drug induced
- resistance training
- adipose tissue
- body composition
- liver fibrosis
- cardiovascular events
- placebo controlled
- health information
- current status
- health insurance
- double blind